Study Reveals Significant Risk Reduction with Elixir Medical Bioadaptor
Elixir Medical announced new clinical results for its DynamX bioadaptor coronary implant system, featuring a novel design to restore blood flow and treat coronary artery disease (CAD) symptoms.
The sirolimus-eluting DynamX bioadaptor addresses existing issues with stent devices, allowing the artery to heal and return to natural motion after support is no longer needed.
Elixir Medical won FDA breakthrough device designation for DynamX and has a CE mark, although it remains investigational in the U.S.
The company aims to return the diseased vessel to a more normal condition with its DynamX bioadaptor.
The company previously shared positive findings for the system in May.
Author's summary: Elixir Medical's DynamX bioadaptor shows promise.
More News
- Art the Clown Owes One of His 'Terrifier' Actresses a Lot of Money
- New president of The Church of Jesus Christ of Latter-day Saints inherits a global faith far more diverse than many realize – Baptist News Global
- Patrick Mahomes’ immediate words on Travis Kelce after victory in the Chiefs Commanders game
- Liverpool vs. Crystal Palace: Carabao Cup team news & TV info
- Randomly-textured lithium niobate gives snapshot spectrometer a boost – Physics World
- Travelzoo: Q3 Earnings Snapshot - WTOP News
- Art the Clown Owes One of His 'Terrifier' Victims a Lot of Money
- Bitcoin Miner TeraWulf (WULF) Stock Jumps 25% On AI News
- Gavin Newsom Says He Has 'No Interest' in Appearing on Joe Rogan's Podcast: 'I'm Moving On' | Video
- Quick Strike Podcast: Use This Key Baitfish to Catch Your Bass of a Lifetime